U.S. health regulators on Friday approved expanding the heart benefit claims Ama...
- U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.
Vascepa, a highly purified form of omega-3 fatty acid, won U.S. approval in 2012 to lower high triglycerides - a type of blood fat that can increase the risk of heart disease. Vascepa has been heralded as a potential game changer in the cardiovascular disease market by Wall Street analysts. Vascepa has been highlighted as a cost-effective add-on to statins by the Institute for Clinical and Economic Review. The therapy’s annual cost based on list price of around $3,600 is much lower than the non-profit group’s recommended value-based price range of $6,300 to $9,200.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Senate confirms Dr. Stephen Hahn as FDA commissionerThe US Senate on Thursday confirmed Dr. Stephen Hahn to be the next commissioner of the US Food and Drug Administration. The Senate vote was 72 to 18.
Consulte Mais informação »
The FDA is investigating 3 separate E. coli outbreaksJust days after health officials urged Americans to throw out their salad kits over E. coli concerns, the Food and Drug Administration announced it's investigating three separate E. coli outbreaks linked to salad products.
Consulte Mais informação »
Senate confirms Stephen Hahn as new FDA commissionerStephen Hahn is poised to take the helm of the agency amid national concern around youth nicotine use with e-cigarettes and lung injuries connected to illicit vaping products.
Consulte Mais informação »
U.S. FDA gives early approval to Sarepta's DMD gene therapyThe U.S. Food and Drug Administration on Thursday granted an early approval to S...
Consulte Mais informação »
Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drugSarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved...
Consulte Mais informação »